Furthermore, for the v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ErbB2)/human epidermal growth factor receptor 2 (HER2) antibody (trastuzumab)-resistant cancer cells (CT26-her2 cells) xenografted tumor, a combination treatment of the PRMT5 inhibitor and Trastuzumab dramatically reduced tumor growth. Here, PRMT5 is linked to neoplasm.